Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

PURPOSE: RTOG 0617 compared standard-dose (SD; 60 Gy) versus high-dose (HD; 74 Gy) radiation with concurrent chemotherapy and determined the efficacy of cetuximab for stage III non–small-cell lung cancer (NSCLC). METHODS: The study used a 2 × 2 factorial design with radiation dose as 1 factor and ce...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Bradley, Jeffrey D., Hu, Chen, Komaki, Ritsuko R., Masters, Gregory A., Blumenschein, George R., Schild, Steven E., Bogart, Jeffrey A., Forster, Kenneth M., Magliocco, Anthony M., Kavadi, Vivek S., Narayan, Samir, Iyengar, Puneeth, Robinson, Clifford G., Wynn, Raymond B., Koprowski, Christopher D., Olson, Michael R., Meng, Joanne, Paulus, Rebecca, Curran, Walter J., Choy, Hak
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2020
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7048161/
https://ncbi.nlm.nih.gov/pubmed/31841363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01162
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller